Plus Therapeutics rises as it secures new billing code for cancer test

Cerenome

07/04/2026 12:54

** Shares of biotech firm Plus Therapeutics PSTV.O rise 3.6% to $3.45 premarket

** Co says the American Medical Association approved a new billing code for its CNSide test, effective July 1, 2026

** CNSide is used to detect cancer cells in spinal fluid in patients whose cancer has spread to the brain and spinal cord, a serious and often hard‑to‑diagnose condition - PSTV

** Says the new code should make it easier for doctors and hospitals to bill insurers, supporting wider use of the test

** Co says the approval marks a key step in the U.S. commercial rollout of its diagnostics business

** As of last close, stock down ~21% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))